NCT03963154进行中（未招募）1 期
STREAM: A Phase 1/2, Open-label, Safety, Tolerability and Preliminary Efficacy Study of Implantation Into One Eye of hESC-derived RPE in Patients With Retinitis Pigmentosa Due to Monogenic Mutation
Centre d'Etude des Cellules Souches2 个研究点 分布在 1 个国家目标入组 7 人开始时间: 2019年8月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 7
- 试验地点
- 2
- 主要终点
- Safety assessment
研究概览
简要总结
Phase I/II open-label, safety, tolerability and preliminary efficacy study of implantation into one eye of hESC-derived RPE (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE)) in patients with retinitis pigmentosa due to monogenic mutation.
Study non randomized single group assignment consisting in 2 sequential cohorts of patients:
- First cohort of 2 patients with very advanced loss of visual acuity (legally blind)
- Second cohort of 10 patients with less advanced loss of visual acuity:
详细描述
Monocentric study (Hospital of 15-20 at Paris) of duration of 106 weeks.
At total,12 evaluable patients will be enrolled and assigned in 2 cohorts as described above in brief summary.
Expected follow-up for one patient is about 64 weeks including 8 weeks of screening and baseline period and 56 weeks of follow-up after implantation of hESC-derived RPE.
After 56 weeks of follow-up, patients will be enrolled in a long term follow-up study during 4 additional years.
The primary objective is to assess safety and tolerability of implantation of the Investigational Medecinal Product (ISTEM-01) in patients with retinitis pigmentosa.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented diagnosis of retinitis pigmentosa based on a genetic test confirming the presence of a monogenic mutation that affects a gene involved in the visual signalling process specifically at the level of RPEs, namely RPE65 or LRAT, or MerTK
- •18 years old ≤ Age ≤ 65 years old
- •For patient of the first cohort:
- •Visual acuity ≤ 20/200 in the best eye (legally blind)
- •For patient of the second cohort:
- •20/63 > Visual acuity > 20/200 in the worst eye And
- •Visible photoreceptor outer nuclear layer (ONL) on a spectral domain optical coherence tomography (OCT) scan
- •For the two cohorts:
- •Negative serum pregnancy test in women of childbearing potential (a woman who is two years post-menopausal confirmed by a physician or surgically sterile is not considered to be of childbearing potential)
- •Female patients of childbearing potential (if sexually active), committed to use two methods of contraception starting from the enrollment, during Mycophenolate Mofetil (MMF) treatment and for 6 weeks after the last dose of MMF
- •Sexually active men (including vasectomized men) committed to use condoms during from the first day of MMF treatment and for at least 90 days after cessation of treatment
- •Signed informed consents by the patient or legal guardian(s). For patients unable to give consent, authorization to participate to the study will be collected close to their legally authorized representative
- •Affiliated to or a beneficiary of a health care system
排除标准
- •- Patient unable or unwilling to comply with the protocol requirements
- •History of allergy or sensitivity to one of the products used during the study
- •Patients with known serious allergies to the fluorescein
- •Patients with a contraindication to general anesthesia
- •Prior treatment with a gene or cell therapy product
- •Patients with chronic hepatitis B or C, i.e. positive hepatitis B surface antigen or hepatitis C RNA viral load positive
- •Patients infected with Human immunodeficiency virus (HIV)
- •Anti-HLA antibodies positive at screening
- •Pregnancy or breastfeeding
- •Presence of any ocular disease or ocular media opacity which in the opinion of the investigator precludes accurate evaluation
- •Participation in another drug or device clinical study within last 6 months prior to baseline
- •Patients known to be affected by pathologies for which the symptoms or associated treatments can alter the visual function and/or affect the retina
- •Systemic corticosteroid therapy or other immunosuppressive / immunomodulating or anti-retroviral drugs within 2 months prior to baseline
- •Patients with a contraindication to immunosuppressive/immunomodulating therapy (MMF) such as severe chronic renal impairment, severe digestive system disease, Lesch-Nyhan disease, Kelley-Seegmiller syndrome...
- •Acute illness or infection within 4 weeks of the anticipated administration of study medication which may interfere with study assessments and immunosuppressive/immunomodulating therapy
- •Any other condition or history that, in the opinion of the Investigator, may compromise the safety or compliance of the patient or would preclude the patient from successful completion of the study
结局指标
主要结局
Safety assessment
时间窗: From Baseline until Week 56
Safety and tolerability measured by the incidence of Adverse Events or Serious Adverse Events throughout the study
次要结局
- Placement of the therapeutic patch(From Baseline until Week 56)
- Position of therapeutic patch(From baseline until Week 56)
- Change in leakage or perfusion(At baseline and weeks 24, 48, and 56)
- Change in thickness of RPE layer(At weeks 4, 8, 16, 24, 36, 48 and 56)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's DiseaseAlzheimer DiseaseNCT04971733Eisai Inc.8
Unknown
1 期
A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid TumorsNon-small Cell Lung CancerNCT05329298Betta Pharmaceuticals Co., Ltd.90
已完成
2 期
A Study of NOE-115 in Women With Vasomotor Symptoms Due to MenopauseMenopause SyndromeHot FlashesMenopauseNCT06385795Noema Pharma AG40
招募中
1 期
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid TumorsAdvanced Solid TumorsGenital Neoplasm, FemaleUrogenital NeoplasmsNeoplasms by SitePapillomavirus InfectionEpstein-Barr Virus InfectionsCarcinomaNeoplasmsVulvar NeoplasmsVulvar DiseasesAbdominal NeoplasmLung NeoplasmNSCLC (Non-small Cell Lung Cancer)Colorectal CancerNCT05592626Marengo Therapeutics, Inc.366
进行中（未招募）
1 期
A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT05951608Akeso216